Kyle L Kolaja
Cellular Dynamics International
Kyle Kolaja is currently Vice President, Business Development at Cellular Dynamics, International, a leading developer of stem cell technologies for in vitro drug development, in vivo cellular therapeutics, and stem cell banking. In this role, Dr. Kolaja leverages his 15 years of pharmaceutical experience as a toxicology thought leader to seek and establish novel preclinical and clinical applications of pluripotent stem cells and their derived tissues. Prior to joining CDI, Dr. Kolaja was Leader/Global Head of Predictive Toxicology Screens and Investigative Toxicology at Roche, where he oversaw laboratories in US and Europe that conducted all safety screening assays, provided toxicology support to projects, and applied stem cell derived tissues to safety. Prior to joining Roche, Dr. Kolaja was Vice President of Chemogenomics and Toxicology at Iconix Pharmaceuticals and prior to that, was a project toxicologist and site head of investigative toxicology at Searle/Pharmacia. Dr. Kolaja has served as President of the Society of Toxicology's Drug Discovery Toxicology Specialty Section, is currently President of the Stem Cells and Toxicology Specialty Section, and previously served on the Board of Directors for the American Boards Of Toxicology. Dr. Kolaja is currently an Associate Editor of the SOT's Journal Toxicological Sciences. Dr. Kolaja has nearly 70 peer-reviewed publications and reviews including 12 on applications of stem cell derived tissues in early safety, received his BS from Michigan State University and his Ph.D. in Toxicology from Indiana University (mentor James Klaunig) and conducted his post-doctoral research at the University of Kansas (mentor Curt Klaassen).